Amgen 2004 R&D Goals Focus On Oncology, Osteoporosis Products
Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies
Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies